Tadashi Inoue

This inventor holds 14 USPTO granted patents and 2 published patent applications, plus 6 CIPO patents and 5 EPO patents. Top assignees: Raqualia Pharma Inc., Pfizer Corporation, Fuji Yakuhin Co., Ltd. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tadashi Inoue. Retrieved from https://idiyas.com/inventor/tadashi-inoue-e98xwbyz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 2)

% Patents Active = 14.3

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

Aichi-ken, JP (2007 - 2011)
Chita-gun, JP (2012)
Saitama, JP (2015)
Aichi, JP (2014 - 2016)

Company Filing History:

Fuji Yakuhin Co., Ltd

patents

Years Active: 2007-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673946 - Pyrimidin-4(3H)-one derivatives as TRPV4 antagonists (2026-07-07),

2. 12496293 - Solid pharmaceutical preparation (2025-12-16),

3. 9522140 - Aryl substituted carboxamide derivatives as calcium or sodium channel blockers (2016-12-20),

4. 9199970 - 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile crystalline polymorph and production method therefor (2015-12-01),

5. 9101616 - Aryl substituted carboxamide derivatives as calcium or sodium channel blockers (2015-08-11),

6. 9051296 - Aryl carboxamide derivatives as TTX-S blockers (2015-06-09),

7. 8969383 - Picolinamide derivatives as TTX-S blockers (2015-03-03),

8. 8809380 - Picolinamide derivatives as TTX-S blockers (2014-08-19),

9. 8252790 - [object Object] (2012-08-28),

10. 7915448 - Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists (2011-03-29),

11. 7622589 - Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists (2009-11-24),

12. 7566739 - Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists (2009-07-28),

13. 7514457 - Substituted aryloxymethyl bicyclicmethyl acetamide compounds (2009-04-07),

14. 7214824 - [object Object] (2007-05-08),

Title: Innovations of Tadashi Inoue

Introduction

Tadashi Inoue is a prominent inventor based in Aichi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target calcium and sodium channels. With a total of 14 patents to his name, Inoue's work has the potential to impact the treatment of various medical conditions.

Latest Patents

One of Inoue's latest patents involves aryl substituted carboxamide derivatives that act as calcium or sodium channel blockers. This invention relates to compounds that have blocking activities of T-type calcium channels or voltage-gated sodium channels, which are crucial in treating disorders where these channels are involved. The patent also covers pharmaceutical compositions that include these compounds, emphasizing their therapeutic potential.

Another notable patent is for the crystalline polymorph of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile. This invention provides different crystal forms of a useful pharmaceutical and outlines a production method for these polymorphs. The ability to produce various crystal forms enhances the compound's applicability in pharmaceutical formulations.

Career Highlights

Throughout his career, Inoue has worked with notable companies such as Raqualia Pharma Inc. and Pfizer Corporation. His experience in these organizations has allowed him to collaborate with leading experts in the pharmaceutical industry, further advancing his research and innovations.

Collaborations

Inoue has collaborated with esteemed colleagues, including Yoshimasa Arano and Mikio Morita. These partnerships have contributed to the successful development of his patented inventions and have fostered a collaborative environment for innovation.

Conclusion

Tadashi Inoue's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work on calcium and sodium channel blockers holds promise for the treatment of various diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.